Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma
ChiCTR2300073026Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in squamous cell carcinoma of the hypopharynx, sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Disease-free survival. Started Jul 2023; status: recruiting.
02
Drugs
capecitabine
03
Conditions
squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ChiCTR2300073026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073026.